secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001193125-24-083352
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion reports initial data from first two T1D patients dosed with BMF-219; C-peptide increased
--------------------------------------------------------------------------------

- Patient 1 (200 mg): fasting C-peptide +57% at week 4, +80% at week 8; MMTT C-peptide index AUC +12% and +40%.
- Patient 2 (100 mg): fasting C-peptide +16% at week 4; MMTT C-peptide index AUC +30%; reduced daily insulin usage.
- BMF-219 well tolerated in both patients; no safety signals reported.
- Open-label portion of COVALENT-112 (n=40) with 12-week dosing data expected in 2024.
- First type 2 diabetes patient in COVALENT-111 discontinued metformin after week 40 with improved glycemic control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312524083352/0001193125-24-083352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312524083352/d765540d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-083352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer